Palisade Bio

PALINasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$202.154 M

$1.16 -7.20%

Close of 6 Nov 2026

As of 6 Nov 2026, Palisade Bio (PALI) has a market capitalization of $202.2M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$0.00

#3616 by revenue

Earnings

-$16.8M

Loss-making

Shares outstanding

174,270,558

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#94Protalix BioTherapeuticsPLX$202.6M
#95Artiva BiotherapeuticsARTV$202.4M
#96Palisade BioPALI$202.2M
#97Inhibikase TherapeuticsIKT$201.6M
#98CompugenCGEN$183.0M

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Palisade Bio, worth $28.8K. Grants and option exercises are excluded.

Donald Allen Williams$28.8K
20,000 shares at $1.44 on 1 Oct 2026 · filed 5 Oct 2026

What if Palisade Bio were worth as much as…

Open the what-if tool →

Gold $28.2T

$162,028.94

Per share 139,680× higher

Bitcoin $1.53T

$8,767.10

Per share 7,558× higher

Apple $5.02T

$28,781.58

Per share 24,812× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Palisade Bio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.